|
C14ORF37 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.16660001051139E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.65129998563884E-09 |
| Normal-vs-Stage2 |
4.621700E-02 |
| Normal-vs-Stage3 |
1.91470999999499E-05 |
| Normal-vs-Stage4 |
2.56640000362296E-08 |
| Stage1-vs-Stage2 |
3.571800E-02 |
| Stage1-vs-Stage3 |
5.269000E-01 |
| Stage1-vs-Stage4 |
2.898200E-01 |
| Stage2-vs-Stage3 |
1.595390E-01 |
| Stage2-vs-Stage4 |
1.347540E-02 |
| Stage3-vs-Stage4 |
1.872820E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.95390001137497E-09 |
| Normal-vs-AfricanAmerican |
1.640780E-03 |
| Normal-vs-Asian |
2.75620000045329E-07 |
| Caucasian-vs-AfricanAmerican |
6.305400E-01 |
| Caucasian-vs-Asian |
2.979000E-01 |
| AfricanAmerican-vs-Asian |
2.487600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.68040000025904E-07 |
| Normal-vs-Female |
3.21380000389837E-09 |
| Male-vs-Female |
8.922800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.53510000161705E-08 |
| Normal-vs-Age(41-60Yrs) |
1.177600017499E-09 |
| Normal-vs-Age(61-80Yrs) |
2.618900E-04 |
| Normal-vs-Age(81-100Yrs) |
2.698800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.485200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.864600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.656000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.672000E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.515830E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.082400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.563800E-01 |
| Classical-VS-Follicular |
2.054200E-01 |
| Classical-VS-Other |
5.302400E-01 |
| Classical-VS-Normal |
7.7235999818015E-09 |
| Tall-VS-Follicular |
2.671000E-01 |
| Tall-VS-Other |
6.875000E-01 |
| Tall-VS-Normal |
1.87665999999975E-05 |
| Follicular-VS-Other |
3.525800E-01 |
| Follicular-VS-Normal |
4.007500E-04 |
| Other-VS-Normal |
1.797830E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.7369000016032E-08 |
| Normal-vs-N1 |
5.50280000455317E-08 |
| N0-vs-N1 |
1.972760E-01 |
|
|
